Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Bartenstein

Showing results (11-20 of 162) with videos related to

Pageof 17
Sort By:
Mini Reviews in Medicinal Chemistry|July 19, 2011
Chelating agents and their use in radiopharmaceutical sciencesB Wängler, R Schirrmacher, P Bartenstein, et al.
Nuklearmedizin. Nuclear Medicine|August 1, 1990
[Immunoscintigraphy of the hematopoietic bone marrow in osteomyelofibrosis]P Bartenstein, B Kirchner, K Scheidhauer, et al.
European Journal of Gynaecological Oncology|June 27, 2018
Metastatic mammary carcinoma despite histologically negative sentinel lymph nodes: are there any indicators for estimating recurrence and metastasis rates?M Weiss, S Siegert, P Bartenstein, et al.
Brain : a Journal of Neurology|October 8, 1998
Reciprocal inhibitory visual-vestibular interaction. Visual motion stimulation deactivates the parieto-insular vestibular cortexT Brandt, P Bartenstein, A Janek, et al.
Nuklearmedizin. Nuclear Medicine|August 1, 1992
[Cortical dysplasia as an epileptogenic focus: reduced binding of 123I-iomezanil with barely perceptible 99mTc-HMPAO SPECT]P Bartenstein, C Lehmenkühler, J Sciuk, et al.
Current Medicinal Chemistry|February 17, 2010
Click-chemistry reactions in radiopharmaceutical chemistry: fast & easy introduction of radiolabels into biomolecules for in vivo imagingC Wängler, R Schirrmacher, P Bartenstein, et al.
Beitrage Zur Infusionstherapie = Contributions to Infusion Therapy|January 1, 1988
[Improved scintigraphic imaging using cell separator-enriched. indium-111-oxinate marked granulocytes]U Taborski, P Bartenstein, N Müller, et al.
Nuklearmedizin. Nuclear Medicine|March 22, 2000
[Combination systems for SPECT, coincidence, PET and CT. Technical spectrum, operating assumptions and possible areas of application]U Büll, P Bartenstein, C M Kirsch, et al.
The American Journal of Psychiatry|September 5, 2001
Normal PET after long-term ECTI Anghelescu, C J Klawe, P Bartenstein, et al.
Nuklearmedizin. Nuclear Medicine|May 7, 2004
Primary hyperoxaluria type 1: appearance in FDG PET, bone- and bone marrow scintigraphyC T Kadalie, O Schreiner, H U Kauczor, et al.
Pageof 17

Showing results (11-20 of 162) with videos related to

Sort By:
Pageof 17
Mini Reviews in Medicinal Chemistry|July 19, 2011
Chelating agents and their use in radiopharmaceutical sciencesB Wängler, R Schirrmacher, P Bartenstein, et al.
Nuklearmedizin. Nuclear Medicine|August 1, 1990
[Immunoscintigraphy of the hematopoietic bone marrow in osteomyelofibrosis]P Bartenstein, B Kirchner, K Scheidhauer, et al.
European Journal of Gynaecological Oncology|June 27, 2018
Metastatic mammary carcinoma despite histologically negative sentinel lymph nodes: are there any indicators for estimating recurrence and metastasis rates?M Weiss, S Siegert, P Bartenstein, et al.
Brain : a Journal of Neurology|October 8, 1998
Reciprocal inhibitory visual-vestibular interaction. Visual motion stimulation deactivates the parieto-insular vestibular cortexT Brandt, P Bartenstein, A Janek, et al.
Nuklearmedizin. Nuclear Medicine|August 1, 1992
[Cortical dysplasia as an epileptogenic focus: reduced binding of 123I-iomezanil with barely perceptible 99mTc-HMPAO SPECT]P Bartenstein, C Lehmenkühler, J Sciuk, et al.
Current Medicinal Chemistry|February 17, 2010
Click-chemistry reactions in radiopharmaceutical chemistry: fast & easy introduction of radiolabels into biomolecules for in vivo imagingC Wängler, R Schirrmacher, P Bartenstein, et al.
Beitrage Zur Infusionstherapie = Contributions to Infusion Therapy|January 1, 1988
[Improved scintigraphic imaging using cell separator-enriched. indium-111-oxinate marked granulocytes]U Taborski, P Bartenstein, N Müller, et al.
Nuklearmedizin. Nuclear Medicine|March 22, 2000
[Combination systems for SPECT, coincidence, PET and CT. Technical spectrum, operating assumptions and possible areas of application]U Büll, P Bartenstein, C M Kirsch, et al.
The American Journal of Psychiatry|September 5, 2001
Normal PET after long-term ECTI Anghelescu, C J Klawe, P Bartenstein, et al.
Nuklearmedizin. Nuclear Medicine|May 7, 2004
Primary hyperoxaluria type 1: appearance in FDG PET, bone- and bone marrow scintigraphyC T Kadalie, O Schreiner, H U Kauczor, et al.
Pageof 17